113 related articles for article (PubMed ID: 10939753)
1. Immune response in hemodialysis patients: is there any difference when low and high iPTH levels are compared?
Tzanno-Martins C; Futata E; Jorgetti V; Duarte AJ
Clin Nephrol; 2000 Jul; 54(1):22-9. PubMed ID: 10939753
[TBL] [Abstract][Full Text] [Related]
2. Restoration of impaired T-cell proliferation after parathyroidectomy in hemodialysis patients.
Tzanno-Martins C; Futata E; Jorgetti V; Duarte AJ
Nephron; 2000 Mar; 84(3):224-7. PubMed ID: 10720892
[TBL] [Abstract][Full Text] [Related]
3. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
Nasri H; Baradaran A
J Ayub Med Coll Abbottabad; 2004; 16(2):3-8. PubMed ID: 15455608
[TBL] [Abstract][Full Text] [Related]
4. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
Nasri H; Baradaran A; Naderi AS
Acta Med Austriaca; 2004 Aug; 31(3):67-72. PubMed ID: 15515479
[TBL] [Abstract][Full Text] [Related]
5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
6. Low response to HBsAg vaccine in chronic renal failure patients is not due to intrinsic defect of B cells.
Krishnamurthy G; Kher V; Naik S
Scand J Urol Nephrol; 2002; 36(5):377-82. PubMed ID: 12487744
[TBL] [Abstract][Full Text] [Related]
7. Immunologic disturbances and levels of parathyroid hormone in uremic patients in replacement dialysis therapy.
Angelini D; Carlini A; Mazzotta L; Mei E; Grassi R; Giusti R; Neri M; Fiorini I; Antonelli A
Clin Nephrol; 1994 Oct; 42(4):246-50. PubMed ID: 7834917
[TBL] [Abstract][Full Text] [Related]
8. Determinants of soluble CD23 antigen levels in hemodialysis patients: effect of 1.25 dihydroxyvitamin D3 and recombinant human erythropoietin treatment.
Altun B; Erdem Y; Usalan C; Arici M; Haznedaroglu IC; Yasavul U; Turgan C; Caglar S; Kirazli S
Clin Nephrol; 1999 Oct; 52(4):230-8. PubMed ID: 10543325
[TBL] [Abstract][Full Text] [Related]
9. Initial dosing of paricalcitol based on PTH levels in hemodialysis patients with secondary hyperparathyroidism.
Mitsopoulos E; Zanos S; Ginikopoulou E; Kyriklidou P; Meimaridou D; Sakellariou G
Am J Kidney Dis; 2006 Jul; 48(1):114-21. PubMed ID: 16797393
[TBL] [Abstract][Full Text] [Related]
10. Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen.
Yan S; Marguet D; Dobers J; Reutter W; Fan H
Eur J Immunol; 2003 Jun; 33(6):1519-27. PubMed ID: 12778469
[TBL] [Abstract][Full Text] [Related]
11. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
[TBL] [Abstract][Full Text] [Related]
12. Effect of blood purification on plasma levels of intact parathyroid hormone in patients with chronic renal failure.
Liu J; Liu ZQ; Tao HQ
Di Yi Jun Yi Da Xue Xue Bao; 2004 Feb; 24(2):234-5. PubMed ID: 14965840
[TBL] [Abstract][Full Text] [Related]
13. In vivo assessment of intact parathyroid hormone adsorption by different dialysis membranes during hemodialysis.
Balducci A; Coen G; Manni M; Perruzza I; Fassino V; Sardella D; Grandi F
Artif Organs; 2004 Dec; 28(12):1067-75. PubMed ID: 15554934
[TBL] [Abstract][Full Text] [Related]
14. Parathyroid hormone levels, calcium-channel blockers, and the dyslipidemia of nondiabetic hemodialysis patients.
Zanos S; Mitsopoulos E; Sakellariou G
Ren Fail; 2005; 27(2):163-9. PubMed ID: 15807180
[TBL] [Abstract][Full Text] [Related]
15. Cellular immunity and levels of parathyroid hormone in uremic patients receiving hemodialysis.
Griveas I; Visvardis G; Papadopoulou D; Mitsopoulos E; Kyriklidou P; Manou E; Meimaridou D; Ginikopoulou E; Sakellariou G; Fleva A; Zilidou R; Paulitou A
Ren Fail; 2005; 27(3):275-8. PubMed ID: 15957542
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic and functional analysis of peripheral blood mononuclear cells in generalised aggressive and chronic periodontitis patients.
Emingil G; Karaarslan F; Keskinoğlu A; Coker I; Atilla G
J Int Acad Periodontol; 2001 Oct; 3(4):87-94. PubMed ID: 12666947
[TBL] [Abstract][Full Text] [Related]
17. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
Greenbaum LA; Benador N; Goldstein SL; Paredes A; Melnick JZ; Mattingly S; Amdahl M; Williams LA; Salusky IB
Am J Kidney Dis; 2007 Jun; 49(6):814-23. PubMed ID: 17533024
[TBL] [Abstract][Full Text] [Related]
18. Circulating 1-84 PTH and large C-terminal PTH fragment levels in uremia.
Kazama JJ; Omori T; Ei I; Ei K; Oda M; Maruyama H; Narita I; Gejyo F; Shigematsu T; Fukagawa M
Clin Exp Nephrol; 2003 Jun; 7(2):144-9. PubMed ID: 14586733
[TBL] [Abstract][Full Text] [Related]
19. B-cell activation and immunoregulation in end-stage renal disease patients receiving hemodialysis.
Raskova J; Ghobrial I; Czerwinski DK; Shea SM; Eisinger RP; Raska K
Arch Intern Med; 1987 Jan; 147(1):89-93. PubMed ID: 3492183
[TBL] [Abstract][Full Text] [Related]
20. [Increased in vitro and ex vivo proliferation of erythroid precursors induced by calcitriol in chronic renal failure. Synergistic effect with rHuEPO].
Aucella F; Gatta G; Vigilante M; Scalzulli RP; Mantuano S; Carotenuto M; Stallone C
G Ital Nefrol; 2002; 19(2):137-42. PubMed ID: 12195411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
